Last checked at 19 Mar 2019 17:05
MaxCyte, Inc.
("MaxCyte" or the "Company")
Director Dealings
Issue of Equity
Gaithersburg, Maryland - 19 March 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, announces that J. Stark Thompson, Non-Executive Chairman of the Company, has exercised options over 25,000 shares of common stock of 0.1 pence of the Company ("Common Stock") ("Exercise"). In order to fund a near term personal tax liability, the 25,000 new shares of Common Stock issued pursuant to the Exercise ("New Common Stock") have today been sold by Dr Thompson at a price of 180 pence per Common Stock ("Sale"). Dr Thompson has no current intention of making further sales of MaxCyte shares.
Following the Exercise and Sale, Dr Thompson's holding of Common Stock remains unchanged at a total of 110,918 Common Stock representing a total of 0.2% of the issued share capital of the Company. Dr Thompson holders a further 239,533 options over Common Stock.
Total voting rights
The New Common Stock will be allocated out of the common stock the subject of the block listing announced on 2 May 2017. The New Common Stock will rank pari passu with the existing shares of common stock of the Company. The total issued stock capital of the Company following the above will be 57,316,500 shares of common stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.
The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 51,357,764 and the number of restricted shares of Common Stock trading under the symbol 'MXCS' is 5,958,736.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | J. Stark Thompson | |
2 | Reason for the notification | ||
a) | Position/status | Non-Executive Chairman and PDMR | |
b) | Initial notification/Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | MaxCyte, Inc. | |
b) | LEI | 54930053YHXULRFCU991 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument | Exercise of options and Sale of Common Stock | |
b) | Identification Code | US57777K1060 | |
c) | Nature of the transaction | Exercise of options and Sale of Common Stock by PDMR | |
d) | Price(s) and volume(s) | Price(s) | Volume(s) |
N/A 180.00 pence
| 25,000 (option exercise) 25,000 (sale of common stock) | ||
e) | Aggregated information - Aggregated volume - Price | N/A 25,000 180.00 (sale of common stock) | |
f) | Date of the transaction | 19 March 2019 | |
g) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | |
About MaxCyte
MaxCyte is a clinical-stage global cell-based medicines and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA™ therapies for its own pipeline, with its first drug candidate in a Phase 1 clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its core business, MaxCyte leverages its Flow Electroporation® Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, has more than 70 partnered program licenses in cell therapy including more than 35 licensed for clinical use. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.
For further information, please contact:
MaxCyte Inc. Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer
| +1 301 944 1660 |
Nominated Adviser and Broker Panmure Gordon Emma Earl Freddy Crossley Corporate Broking James Stearns |
+44 (0)20 7886 2500 |
Financial PR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh Sukaina Virji |
+44 (0)203 709 5700 maxcyte@consilium-comms.com |